Eli Lilly and Company (LLY)vsTheravance Biopharma Inc (TBPH)
LLY
Eli Lilly and Company
$966.99
+1.95%
HEALTHCARE · Cap: $869.41B
TBPH
Theravance Biopharma Inc
$16.52
-2.88%
HEALTHCARE · Cap: $876.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 65716% more annual revenue ($72.25B vs $109.78M). TBPH leads profitability with a 104.3% profit margin vs 35.0%. TBPH trades at a lower P/E of 7.6x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TBPH
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+69.2%
Fair Value
$63.35
Current Price
$16.52
$46.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Every $100 of equity generates 50 in profit
Keeps 104 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
15.0% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -33.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TBPH
The strongest argument for TBPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 104.3% and operating margin at -33.1%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TBPH
The primary concerns for TBPH are EPS Growth, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while TBPH is a mature play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 52/100), backed by strong 35.0% margins and 55.5% revenue growth. TBPH offers better value entry with a 69.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?